Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference
暂无分享,去创建一个
[1] A. Nanji,et al. Serum alanine aminotransferase to aspartate aminotransferase ratio and degree of fatty liver in morbidly obese patients. , 1986, Enzyme.
[2] R. Fisher,et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[3] H. Gin,et al. Maternally Inherited Diabetes and Deafness: A Multicenter Study , 2001, Annals of Internal Medicine.
[4] S. Collins,et al. Up-regulation of UCP-2 gene expression by PPAR agonists in preadipose and adipose cells. , 1997, Biochemical and biophysical research communications.
[5] Marco Zoli,et al. Metformin in non-alcoholic steatohepatitis , 2001, The Lancet.
[6] P. Giral,et al. Survival, liver failure, and hepatocellular carcinoma in obesity‐related cryptogenic cirrhosis , 2002, Hepatology.
[7] K. Petersen,et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. , 2002, The Journal of clinical investigation.
[8] F. Marumo,et al. Nonalcoholic steatohepatitis masquerading as autoimmune hepatitis. , 1997, Journal of clinical gastroenterology.
[9] R. Paraná,et al. Nonalcoholic steatohepatitis: a toxic liver disease in industrial workers. , 1999, Liver.
[10] J. Kinsella,et al. Effect of different dietary triglycerides on liver fatty acids and prostaglandin synthesis by mouse peritoneal cells. , 1992, JPEN. Journal of parenteral and enteral nutrition.
[11] Margaret S. Wu,et al. Role of AMP-activated protein kinase in mechanism of metformin action. , 2001, The Journal of clinical investigation.
[12] N. Alshak,et al. Dietary lecithin, antioxidant and vitamin B complex (LAB) decrease hepatic steatosis on patients with nonalcoholic steatoheaptitis (NASH) , 1998 .
[13] M. Fernández-Bermejo,et al. A wider view on diagnostic criteria of nonalcoholic steatohepatitis. , 2002, Gastroenterology.
[14] R. DeFronzo. Pharmacologic Therapy for Type 2 Diabetes Mellitus , 1999, Annals of Internal Medicine.
[15] R. Lobo,et al. The Importance of Diagnosing the Polycystic Ovary Syndrome , 2000, Annals of Internal Medicine.
[16] A. Lonardo,et al. Apolipoprotein synthesis in nonalcoholic steatohepatitis , 2002, Hepatology.
[17] R. Mortimer,et al. Steatohepatitis associated with limb lipodystrophy. , 1989, Gastroenterology.
[18] R. Varma,et al. Recurrent nonalcoholic steatohepatitis and cirrhosis after liver transplantation. , 1997, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[19] P. Thuluvath,et al. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: A case‐control study , 2000, Hepatology.
[20] R. Batey,et al. Computer Assisted Quantitation of Terminal Hepatic Vein Connective Tissue in the Rat , 1992, Pathology.
[21] E. Bolson,et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. , 2001, The New England journal of medicine.
[22] R. Chamuleau,et al. The effects of ammonia and portal-systemic shunting on brain metabolism, neurotransmission and intracranial hypertension in hyperammonaemia-induced encephalopathy. , 1997, Journal of hepatology.
[23] A. Dulloo. Biomedicine. A sympathetic defense against obesity. , 2002, Science.
[24] W. Kraus,et al. Effects of the amount and intensity of exercise on plasma lipoproteins. , 2002, The New England journal of medicine.
[25] T. Ben-Menachem,et al. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients , 1999, American Journal of Gastroenterology.
[26] W. Kim,et al. Recurrence of nonalcoholic steatohepatitis following liver transplantation. , 1996, Transplantation.
[27] L. N. Valenti,et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. , 2002, Gastroenterology.
[28] F. Schaffner,et al. Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.
[29] C. Day,et al. Steatohepatitis: a tale of two "hits"? , 1998, Gastroenterology.
[30] T. Therneau,et al. An assessment of the role of liver biopsies in asymptomatic patients with chronic liver test abnormalities , 2000, American Journal of Gastroenterology.
[31] A Tremblay,et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. , 1994, The American journal of cardiology.
[32] R. Ross,et al. Racial differences in visceral adipose tissue but not anthropometric markers of health-related variables. , 2000, Journal of applied physiology.
[33] J. Lehmann,et al. Effects of troglitazone and metformin on glucose and lipid metabolism: alterations of two distinct molecular pathways. , 1997, Biochemical pharmacology.
[34] Rahul Krishnarao Patil,et al. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease , 2001, American Journal of Gastroenterology.
[35] S. Lu,et al. Methionine adenosyltransferase and liver disease: it's all about SAM. , 1998, Gastroenterology.
[36] J. Clore,et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. , 2001, Gastroenterology.
[37] W. Dietz,et al. Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents. , 2000, The Journal of pediatrics.
[38] D. Jakubowicz,et al. Role of inositolphosphoglycan mediators of insulin action in the polycystic ovary syndrome. , 2000, Journal of pediatric endocrinology & metabolism : JPEM.
[39] U. Visco-Comandini,et al. Metformin in non-alcoholic steatohepatitis , 2002, The Lancet.
[40] K. Lindor,et al. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study , 2001, American Journal of Gastroenterology.
[41] O. Weiland,et al. Features of the CD4+ T-cell response in liver and peripheral blood of hepatitis C virus-infected patients with persistently normal and abnormal alanine aminotransferase levels. , 2002, Journal of hepatology.
[42] J. Flier,et al. Leptin inhibition of the hypothalamic-pituitary-adrenal axis in response to stress. , 1997, Endocrinology.
[43] J. Patrie,et al. Is NASH underdiagnosed among African Americans? , 2002, American Journal of Gastroenterology.
[44] H. Appelman,et al. Regression of hepatic steatosis in morbidly obese persons after gastric bypass. , 1995, American journal of clinical pathology.
[45] A. J. Mcadams,et al. Liver ultrastructure in abetalipoproteinemia: Evolution of micronodular cirrhosis. , 1974, Gastroenterology.
[46] P. Giral,et al. Liver fibrosis in overweight patients. , 2000, Gastroenterology.
[47] S. Caldwell,et al. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. , 2000, The American journal of medicine.
[48] S. Thung,et al. Hepatic Weber-Christian disease. , 2001, Seminars in liver disease.
[49] J. K. Lee,et al. Role of Hyperinsulinemia and Glucose Intolerance in the Pathogenesis of Nonalcoholic Fatty Liver in Patients with Normal Body Weight , 1998, The Korean journal of internal medicine.
[50] I. Leclercq,et al. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. , 2001, American journal of physiology. Gastrointestinal and liver physiology.
[51] W. van Steenbergen,et al. Liver disturbances in obesity and diabetes mellitus. , 1995, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.
[52] G. Minuk,et al. Clinical hepatology: Profile of an urban, hospital‐based practic , 1996, Hepatology.
[53] H. Cortez‐Pinto,et al. Non-alcoholic fatty liver: another feature of the metabolic syndrome? , 1999, Clinical nutrition.
[54] E. Drenick,et al. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small-bowel bypass. , 1970, The New England journal of medicine.
[55] A. Dulloo. A Sympathetic Defense Against Obesity , 2002, Science.
[56] N. Kaplowitz,et al. Transport of reduced glutathione in hepatic mitochondria and mitoplasts from ethanol‐treated rats: Effect of membrane physical properties and S‐adenosyl‐L‐methionine , 1997, Hepatology.
[57] N. Barzilai,et al. Leptin selectively decreases visceral adiposity and enhances insulin action. , 1997, The Journal of clinical investigation.
[58] T. Saibara,et al. Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis. , 1999, Lancet.
[59] I. Wanless,et al. Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors , 1990, Hepatology.
[60] H Hoppeler. Skeletal muscle substrate metabolism , 1999, International Journal of Obesity.
[61] A. Czaja. Recurrence of nonalcoholic steatohepatitis after liver transplantation. , 1997, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[62] Mark A Pereira,et al. A low-glycemic index diet in the treatment of pediatric obesity. , 2000, Archives of pediatrics & adolescent medicine.
[63] P. Ward,et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. , 1998, Gastroenterology.
[64] Z. Younossi,et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.
[65] J. Ludwig,et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. , 1980, Mayo Clinic proceedings.
[66] M. Dianzani. Uncoupling of oxidative phosphorylation in mitochondria from fatty livers. , 1954, Biochimica et biophysica acta.
[67] C. García-Monzón,et al. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. , 2000, Journal of hepatology.
[68] M. Washington,et al. Recurrence of nonalcoholic steatohepatitis in a liver transplant recipient. , 1997, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[69] A. Zanella,et al. Updated Definitions of Healthy Ranges for Serum Alanine Aminotransferase Levels , 2002, Annals of Internal Medicine.
[70] C. Gluud,et al. Liver morphology in morbid obesity: a literature study. , 1984, International journal of obesity.
[71] H. Cortez‐Pinto,et al. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. , 1999, JAMA.
[72] J. Grove,et al. Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis , 1997, Hepatology.
[73] T. Wadden,et al. AGA technical review on obesity. , 2002, Gastroenterology.
[74] J. Romijn,et al. Hepatic steatosis and very low density lipoprotein secretion: the involvement of apolipoprotein E. , 2001, Journal of hepatology.
[75] F. Trevisani,et al. Mitochondrial oxidative injury and energy metabolism alteration in rat fatty liver: Effect of the nutritional status , 2001, Hepatology.
[76] J. Goldstein,et al. Liver histology abnormalities in the morbidly obese , 1989, Hepatology.
[77] H. Zimmerman,et al. Liver morphology and function tests in obesity and during total starvation , 1967, The American Journal of Digestive Diseases.
[78] J. Kolanowski. A Risk-Benefit Assessment of Anti-Obesity Drugs , 1999, Drug safety.
[79] A. J. Bourne,et al. Non‐alcoholic steatohepatitis in children and adolescents , 2000, The Medical journal of Australia.
[80] G. Farrell. Drugs and Steatohepatitis , 2002, Seminars in liver disease.
[81] C. Mulrow,et al. Does Counseling by Clinicians Improve Physical Activity? A Summary of the Evidence for the U.S. Preventive Services Task Force , 2002, Annals of Internal Medicine.
[82] A. Nanji,et al. Dietary saturated fatty acids reverse inflammatory and fibrotic changes in rat liver despite continued ethanol administration. , 2001, The Journal of pharmacology and experimental therapeutics.
[83] E. Roberts,et al. Nonalcoholic steatohepatitis in children , 2003, Current gastroenterology reports.
[84] M. Ishizaki,et al. Association between hepatic steatosis, insulin resistance and hyperinsulinaemia as related to hypertension in alcohol consumers and obese people. , 1995, Journal of human hypertension.
[85] C. Day. CD14 promoter polymorphism associated with risk of NASH , 2002 .
[86] T. Valle,et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.
[87] M. Matsuda,et al. Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. , 2002, Diabetes.
[88] Shelly C. Lu,et al. Methionine adenosyltransferase 1A knockout mice are predisposed to liver injury and exhibit increased expression of genes involved in proliferation , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[89] K. Ishak,et al. Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. , 1988, Gastroenterology.
[90] N. Ackerman. Protein supplementation in the management of degenerating liver function after jejunoileal bypass. , 1979, Surgery, gynecology & obstetrics.
[91] A. Nanji,et al. Dietary saturated fatty acids: a novel treatment for alcoholic liver disease. , 1995, Gastroenterology.
[92] L. Teichholz. Statin-associated myopathy with normal creatine kinase levels. , 2003, Annals of internal medicine.
[93] D. M. Rocha,et al. Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. , 1999, Diabetes.
[94] Erick M Remer,et al. The utility of radiological imaging in nonalcoholic fatty liver disease. , 2002, Gastroenterology.
[95] L. N. Valenti,et al. Tumor necrosis factor α promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease , 2002 .
[96] M. Lazar,et al. The hormone resistin links obesity to diabetes , 2001, Nature.
[97] G. Gores,et al. Ursodeoxycholic acid or clofibrate in the treatment of non‐alcohol‐induced steatohepatitis: A pilot study , 1996, Hepatology.
[98] F. Schaffner,et al. Effect of weight reduction on hepatic abnormalities in overweight patients. , 1990, Gastroenterology.
[99] M. Laakso,et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial , 2002, The Lancet.
[100] H. Lebovitz,et al. Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men. , 1999, The Journal of clinical endocrinology and metabolism.
[101] D Echeverria,et al. Hepatic ultrasonic changes in workers exposed to perchloroethylene. , 1995, Occupational and environmental medicine.
[102] H. Bonkovsky,et al. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. , 1999, Journal of hepatology.
[103] E. Keeffe,et al. Steatosis and cirrhosis in an obese diabetic. Resolution of fatty liver by fasting. , 1987, Digestive diseases and sciences.
[104] J. Vamecq,et al. Medical significance of peroxisome proliferator-activated receptors , 1999, The Lancet.
[105] E. Mun,et al. Current status of medical and surgical therapy for obesity. , 2001, Gastroenterology.
[106] Michael Karin,et al. Reversal of Obesity- and Diet-Induced Insulin Resistance with Salicylates or Targeted Disruption of Ikkβ , 2001, Science.
[107] J. Hoofnagle,et al. Efficacy and Safety of Troglitazone in the Treatment of Lipodystrophy Syndromes , 2000, Annals of Internal Medicine.
[108] R. Karim,et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome , 2002, Hepatology.
[109] S. Caldwell,et al. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease , 1999, Hepatology.
[110] S. Strom,et al. Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[111] C. Gluud,et al. Hepatic effects of dietary weight loss in morbidly obese subjects. , 1991, Journal of hepatology.
[112] M. Cullen,et al. Nonalcoholic Steatohepatitis , 1997, Annals of Internal Medicine.
[113] A. Tabares,et al. Adaptation to a fish oil diet before inducing sepsis in rats prevents fatty infiltration of the liver. , 1992, JPEN. Journal of parenteral and enteral nutrition.
[114] G. Farrell,et al. Etiopathogenesis of Nonalcoholic Steatohepatitis , 2001, Seminars in liver disease.
[115] C. Gluud,et al. The liver in consecutive patients with morbid obesity: a clinical, morphological, and biochemical study. , 1984, International journal of obesity.
[116] P. Moulin,et al. Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with Type II diabetes , 2000, Diabetologia.
[117] S. Caldwell,et al. Intermittent disconjugate gaze: A novel finding in nonalcoholic steatohepatitis and cryptogenic cirrhosis , 2005, Hepatology.
[118] N. Jones,et al. Exercise limitation in health and disease. , 2000, The New England journal of medicine.
[119] M. Camilo,et al. Tamoxifen-associated steatohepatitis--report of three cases. , 1995, Journal of hepatology.
[120] Ackerman Nb. Protein supplementation in the management of degenerating liver function after jejunoileal bypass. , 1979 .
[121] M. Yamagata,et al. Role of eicosapentaenoic acid in lipid metabolism in the liver, with special reference to experimental fatty liver. , 1994, Clinical therapeutics.
[122] P. Harrigan,et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. , 2002, The New England journal of medicine.
[123] J. Antosiewicz,et al. Suppression of the hydrazine-induced formation of megamitochondria in the rat liver by alpha-tocopherol. , 1994, Experimental and molecular pathology.
[124] B. Vessby. Dietary fat and insulin action in humans , 2000, British Journal of Nutrition.
[125] C. van den Branden,et al. Alterations of peroxisomes in steatosis of the human liver: A quantitative study , 1995, Hepatology.
[126] J. Flier,et al. A Transgenic Model of Visceral Obesity and the Metabolic Syndrome , 2001, Science.
[127] R. Villa,et al. Pharmacology of lazaroids and brain energy metabolism: a review. , 1997, Pharmacological reviews.
[128] E. Schiff,et al. The Use of piogliatazone in menalcoholic stealohepatitis , 2001 .
[129] M. Başaranoǧlu,et al. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. , 1999, Journal of hepatology.
[130] Randall G. Lee,et al. Nonalcoholic steatohepatitis: a study of 49 patients. , 1989, Human pathology.
[131] W. Vogel,et al. Prognosis and life expectancy in chronic liver disease , 1995, Digestive Diseases and Sciences.
[132] Nash Crn. Nonalcoholic steatohepatitis clinical research network , 2003, Hepatology.
[133] R. Hammer,et al. Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. , 1996, The Journal of clinical investigation.
[134] Randall G. Lee,et al. Nonalcoholic steatohepatitis: Tightening the morphological screws on a hepatic rambler , 1995, Hepatology.
[135] Mauro Salizzoni,et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. , 2002, Gastroenterology.
[136] A. Saltiel. New Perspectives into the Molecular Pathogenesis and Treatment of Type 2 Diabetes , 2001, Cell.
[137] M. Baak. Exercise training and substrate utilisation in obesity , 1999, International Journal of Obesity.
[138] B. Spiegelman,et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. , 1995, The Journal of clinical investigation.
[139] S. Caldwell,et al. Subacute liver failure in obese women , 2002, American Journal of Gastroenterology.
[140] A. Franzese,et al. Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children. , 2000, The Journal of pediatrics.
[141] T. Crabtree,et al. Hepatitis C–induced hepatic allograft injury is associated with a pretransplantation elevated viral replication rate , 2000, Hepatology.
[142] S. Caldwell,et al. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis , 2001, American Journal of Gastroenterology.
[143] J. Friedman,et al. Selective deletion of leptin receptor in neurons leads to obesity. , 2001, The Journal of clinical investigation.
[144] F. Santorelli,et al. Uncoupling protein-1 mRNA expression in lipomas from patients bearing pathogenic mitochondrial DNA mutations. , 2000, Biochemical and biophysical research communications.
[145] E. Fisher,et al. Complexity in the Secretory Pathway: The Assembly and Secretion of Apolipoprotein B-containing Lipoproteins* , 2002, The Journal of Biological Chemistry.
[146] D. Pessayre,et al. Mitochondria in Steatohepatitis , 2001, Seminars in liver disease.
[147] A. Terano,et al. Plasma transforming growth factor‐β1 level and efficacy of α‐tocopherol in patients with non‐alcoholic steatohepatitis: a pilot study , 2001, Alimentary pharmacology & therapeutics.
[148] G. Shulman,et al. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[149] P. Armstrong,et al. Amiodarone hepatotoxicity simulating alcoholic liver disease. , 1984, The New England journal of medicine.
[150] J. Lavine. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. , 2000, The Journal of pediatrics.
[151] B. Teusink,et al. Mice Expressing Only the Mutant APOE3Leiden Gene Show Impaired VLDL Secretion , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[152] A. Scheen,et al. Liver abnormalities in severely obese subjects: Effect of drastic weight loss after gastroplasty , 1998, International Journal of Obesity.
[153] R. Swerdlow,et al. Cyclosporin A increases resting mitochondrial membrane potential in SY5Y cells and reverses the depressed mitochondrial membrane potential of Alzheimer's disease cybrids. , 1998, Biochemical and biophysical research communications.
[154] R. Haggitt,et al. Pericentral hepatic fibrosis and intracellular hyalin in diabetes mellitus. , 1980, Gastroenterology.
[155] Q. Cai,et al. Tamoxifen-induced transient multifocal hepatic fatty infiltration , 2000, American Journal of Gastroenterology.
[156] A. Diehl,et al. Animal Models of Steatosis , 2001, Seminars in liver disease.
[157] P. Vajro,et al. Persistent hyperaminotransferasemia resolving after weight reduction in obese children. , 1994, The Journal of pediatrics.
[158] F. Brancati,et al. Nonalcoholic fatty liver disease. , 2002, Gastroenterology.
[159] D. Helinski,et al. A pilot study of orlistat treatment in obese, non‐alcoholic steatohepatitis patients , 2004, Alimentary pharmacology & therapeutics.
[160] G. Brandi,et al. Prevalence of and Risk Factors for Hepatic Steatosis in Northern Italy , 2000, Annals of Internal Medicine.
[161] J. Silverman,et al. Liver pathology in morbidly obese patients with and without diabetes. , 1990, The American journal of gastroenterology.
[162] J. Silverman,et al. Liver pathology in diabetes mellitus and morbid obesity. Clinical, pathological, and biochemical considerations. , 1989, Pathology annual.
[163] J. Björkegren,et al. A Deficiency of Microsomal Triglyceride Transfer Protein Reduces Apolipoprotein B Secretion* , 2000, The Journal of Biological Chemistry.
[164] J. Dixon,et al. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. , 2001, Gastroenterology.
[165] N. Chavez-Tapia,et al. Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease. A double-blind, placebo-controlled trial. , 2004, Annals of hepatology.
[166] M. Lean,et al. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. , 1999, Diabetes care.
[167] S. Gregory,et al. LMNA, encoding lamin A/C, is mutated in partial lipodystrophy , 2000, Nature Genetics.
[168] M. Rosen,et al. Imaging of Hepatic Steatosis , 2001, Seminars in liver disease.
[169] R. Stoohs,et al. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. , 2002, Gastroenterology.
[170] U. Akarca,et al. Treatment of non-alcoholic steatohepatitis with N-acetyl cystein , 2000 .
[171] E. Drenick,et al. Hepatic steatosis after intestinal bypass--prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition. , 1982, Gastroenterology.
[172] R. Hanson,et al. The natural history of nonalcoholic steatohepatitis: A follow‐up study of forty‐two patients for up to 21 years , 1990, Hepatology.
[173] Y. Takei,et al. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. , 2002, Gastroenterology.
[174] R G Shulman,et al. Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting humans with 13C NMR. , 1991, Science.
[175] H. Shimano,et al. Absence of Sterol Regulatory Element-binding Protein-1 (SREBP-1) Ameliorates Fatty Livers but Not Obesity or Insulin Resistance inLep ob /Lep ob Mice* , 2002, The Journal of Biological Chemistry.
[176] J. Björkegren,et al. Blocking the Secretion of Hepatic Very Low Density Lipoproteins Renders the Liver More Susceptible to Toxin-induced Injury* , 2002, The Journal of Biological Chemistry.
[177] Z. Younossi,et al. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[178] H. Nittono,et al. Effect of taurine on the fatty liver of children with simple obesity. , 1996, Advances in experimental medicine and biology.
[179] K. Tanikawa,et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. , 1997, Journal of hepatology.
[180] O. Cummings,et al. Atorvastatin for the treatment of NASH , 2001 .
[181] D. Crabb,et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. , 2002, Gastroenterology.
[182] B. Bacon,et al. Hepatic iron and nonalcoholic fatty liver disease , 1999, Hepatology.
[183] T. Saibara,et al. Bezafibrate for tamoxifeninduced non-alcoholic steatohepatitis , 1999, The Lancet.
[184] E. Schiff,et al. Prevalence of nonalcoholic steatohepalitis among ethnic groups , 2001 .
[185] R. Kuczmarski. Need for body composition information in elderly subjects. , 1989, The American journal of clinical nutrition.
[186] J. Colombel,et al. Hepatic steatosis revealing celiac disease: a case complicated by transitory liver failure. , 1996, The American journal of gastroenterology.
[187] B. Neuschwander‐Tetri,et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions , 1999, American Journal of Gastroenterology.
[188] P. Scheuer,et al. Does a linear pattern of sinusoidal IgA deposition distinguish between alcoholic and diabetic liver disease? , 2008, Liver.
[189] K. Eriksson,et al. Nonalcoholic steatohepatitis in obesity: a reversible condition. , 2009, Acta medica Scandinavica.
[190] A. Frydén,et al. The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients. , 1999, Scandinavian journal of gastroenterology.
[191] R. Shulman,et al. Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. , 1992, The Journal of clinical investigation.
[192] A. West,et al. Clinical and pathological characteristics of hepatotoxicity associated with occupational exposure to dimethylformamide. , 1990, Gastroenterology.
[193] D. Alvaro,et al. Effect of S-adenosyl-L-methionine on ethanol cholestasis and hepatotoxicity in isolated perfused rat liver. , 1995, Digestive diseases and sciences.
[194] G. Loss,et al. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? , 2002, Hepatology.
[195] H. Cortez‐Pinto,et al. Non-alcoholic fatty liver: another feature of the metabolic syndrome? , 1999, Clinical nutrition.
[196] P. Christoffersen,et al. Fatty liver persisting for up to 33 years. A follow-up of the inversen-roholm liver biopsy material. , 2009, Acta medica Scandinavica.
[197] P. Wang,et al. Histamine inhibits chemotaxis, phagocytosis, superoxide anion production, and the production of TNFalpha and IL-12 by macrophages via H2-receptors. , 2001, International immunopharmacology.
[198] M. Perola,et al. Promoter polymorphism of the CD14 endotoxin receptor gene as a risk factor for alcoholic liver disease , 2001, Hepatology.
[199] A. Sasaki,et al. Mortality and causes of death in type 2 diabetic patients. A long-term follow-up study in Osaka District, Japan. , 1989, Diabetes research and clinical practice.
[200] N. Davidson,et al. APOLIPOPROTEIN B: mRNA editing, lipoprotein assembly, and presecretory degradation. , 2000, Annual review of nutrition.
[201] P. Christoffersen,et al. Liver histology in a 'normal' population--examinations of 503 consecutive fatal traffic casualties. , 1977, Scandinavian journal of gastroenterology.
[202] G. Pacini,et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Further evidence for an etiologic association , 2002, Hepatology.
[203] B. Lowell,et al. βAR Signaling Required for Diet-Induced Thermogenesis and Obesity Resistance , 2002, Science.
[204] A. Garg,et al. Editorial: Hepatic steatosis, insulin resistance, and adipose tissue disorders , 2002 .
[205] K. Uysal,et al. Protection from obesity-induced insulin resistance in mice lacking TNF-α function , 1997, Nature.
[206] K. Batts,et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis , 1999, Hepatology.
[207] B. Koneru,et al. Oxidative stress in fatty livers of obese Zucker rats: Rapid amelioration and improved tolerance to warm ischemia with tocopherol , 2001, Hepatology.
[208] S. Friedman,et al. Leptin in hepatic fibrosis: Evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice , 2002, Hepatology.
[209] B. Lowell,et al. Obesity‐related fatty liver is unchanged in mice deficient for mitochondrial uncoupling protein 2 , 2002, Hepatology.
[210] R. Stewart,et al. Weight loss in obese women--exercise v. dietary education. , 1990, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.
[211] S. Malnick,et al. Fatty liver--an additional and treatable feature of the insulin resistance syndrome. , 1999, QJM : monthly journal of the Association of Physicians.
[212] J. Parks,et al. Mitochondrial abnormalities in non-alcoholic steatohepatitis. , 1999, Journal of hepatology.
[213] M. Reitman,et al. Leptin-replacement therapy for lipodystrophy. , 2002, The New England journal of medicine.
[214] F. Brunetti,et al. Liver Involvement in Obese Children (Ultrasonography and Liver Enzyme Levels at Diagnosis and During Follow-up in an Italian Population) , 1997, Digestive Diseases and Sciences.
[215] Brian P. Mulhall,et al. Nonalcoholic steatohepatitis , 2004, Current treatment options in gastroenterology.
[216] P. Scherer,et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action , 2001, Nature Medicine.
[217] T. Peters,et al. Biochemical analysis of hepatic lipid in alcoholic and diabetic and control subjects. , 1983, Clinical science.
[218] P. Scheuer,et al. Liver Damage due to Methotrexate in Patients with Psoriasis , 1971, British medical journal.
[219] D. Pessayre,et al. Premature oxidative aging of hepatic mitochondrial DNA in Wilson's disease. , 1997, Gastroenterology.
[220] B. Neuschwander‐Tetri,et al. Nonalcoholic steatohepatitis: an expanded clinical entity. , 1994, Gastroenterology.
[221] F. Kuhajda,et al. Metformin reverses fatty liver disease in obese, leptin-deficient mice , 2000, Nature Medicine.
[222] G. Marchesini,et al. Association of nonalcoholic fatty liver disease with insulin resistance. , 1999, The American journal of medicine.
[223] Z. Younossi,et al. Is hepatocellular carcinoma part of the natural history of nonalcoholic steatohepatitis? , 2002, Gastroenterology.
[224] A. Bowcock,et al. AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34 , 2002, Nature Genetics.
[225] C. Degott,et al. Liver in obesity. , 1985, Gut.
[226] M. Arrese,et al. Evidence of intestinal bacterial overgrowth in patients with non-alcoholic steato-hepatitis , 2001 .
[227] A. Garg,et al. A Novel Heterozygous Mutation in Peroxisome Proliferator-Activated Receptor-γ Gene in a Patient with Familial Partial Lipodystrophy , 2002 .
[228] M. Dianzani. The content of adenosine polyphosphates in fatty livers. , 1957, The Biochemical journal.
[229] J. H. Johnson,et al. Thiazolidinediones and insulin resistance: peroxisome proliferatoractivated receptor gamma activation stimulates expression of the CAP gene. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[230] Harbans Singh,et al. High prevalence of NASH among Mexican American females with type II diabetes mellitus , 2001 .